Allt inom mfn-ext-nq-company-announcement

Analysis of the first samples from the 30 mg dose group in the NEX-22 Phase I study shows continued promising results

Nanexa announced today that the first pharmacokinetic (PK) samples from the final dose group, 30 mg, in the ongoing Phase I study for NEX-22 have been analyzed. The results show that the PK profile is similar to that of previous dose groups and that plasma exposure continues to increase with higher doses.